The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid LeukemiaErin Clapper(Griffith University), Kathryn F. Tonissen(Griffith University)HematoMay 4, 202110.3390/hemato2020014Cited by 0SaveCiteExport RISWatch citationsRelated PapersCross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment|Antioxidants|2020|17